Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension.

Anwar A, Li M, Frid MG, Kumar B, Gerasimovskaya EV, Riddle SR, McKeon BA, Thukaram R, Meyrick BO, Fini MA, Stenmark KR.

Am J Physiol Lung Cell Mol Physiol. 2012 Jul 1;303(1):L1-L11. doi: 10.1152/ajplung.00050.2012.

PMID:
22582113
2.

Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

Stenmark KR, Tuder RM, El Kasmi KC.

J Appl Physiol (1985). 2015 Nov 15;119(10):1164-72. doi: 10.1152/japplphysiol.00283.2015. Review.

PMID:
25930027
3.

Hypoxic activation of adventitial fibroblasts: role in vascular remodeling.

Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M.

Chest. 2002 Dec;122(6 Suppl):326S-334S. Review.

PMID:
12475810
4.

Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.

Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC.

IUBMB Life. 2005 Jun;57(6):441-7. Review.

PMID:
16012053
5.

Hypoxia induces cell-specific changes in gene expression in vascular wall cells: implications for pulmonary hypertension.

Stenmark KR, Frid M, Nemenoff R, Dempsey EC, Das M.

Adv Exp Med Biol. 1999;474:231-58. Review.

PMID:
10635005
6.

Osteopontin and mucosal protection.

Sodek J, Batista Da Silva AP, Zohar R.

J Dent Res. 2006 May;85(5):404-15. Review.

PMID:
16632752
Items per page

Supplemental Content

Support Center